JAMA
August 31, 2023
Charles L Raison, Gerard Sanacora, Joshua Woolley et al.
493 citations
A single 25-mg dose of synthetic psilocybin, administered with psychological support, produced a clinically significant and sustained reduction in depressive symptoms and functional disability over 43 days in adults with major depressive disorder. In a phase 2 trial of 104 participants, those receiving psilocybin showed a mean 12.3-point greater improvement on the Montgomery-Asberg Depression Rating Scale at day 43 compared with those receiving a niacin placebo. Psilocybin also improved daily functioning and led to more sustained response, though not remission. No serious adverse events occurred, but psilocybin was associated with more overall and severe adverse events.
Curr Top Behav Neurosci
December 10, 2024
Xiaojue Hu, Ingmar Gorman, Elizabeth Nielson
3 citations
Psychedelic Harm Reduction and Integration (PHRI) is a clinical model that combines principles from harm reduction, psychedelic-assisted therapy, mindfulness, and psychodynamic therapy to help clients prepare for and integrate psychedelic experiences without directly administering psychedelics. It uses non-pathologizing, client-empowering strategies, emphasizing non-directive and inner-directed approaches, somatic awareness, and psychological flexibility. The model addresses common integration challenges such as fear, ego dissolution, and increased emotional sensitivity, aiming to translate psychedelic experiences into lasting positive changes while reducing potential harms. The chapter outlines PHRI's theoretical foundations, distinguishes it from other approaches, and explores its clinical application, focusing on the integration phase.